COMP <GO>
UPB vs ANTX // EV/EBITDA & P/E VALUATION
Upstream Bio Inc. (NASDAQ) VS. AN2 Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: UPB 1
— ANTX 1
■ METRIC PARITY
LAST: $3.41 (+4.28%) • MKT CAP: $179.1M
valuation
—
LAST: $4.53 (-3.41%) • MKT CAP: $177.0M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UPB VS. ANTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | UPB | ANTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -16.86% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 20.40% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.01 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.6 | 54.0 | -13.39 | ANTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $179.1M | $177.0M | $2.1M | UPB | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | UPB REV | ANTX REV | UPB GROSS % | ANTX GROSS % | UPB FCF | ANTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.9M | $0 | — | — | -$133.4M | -$29.8M |
| FY 2024 | $2.4M | $0 | — | — | -$59.7M | -$49.3M |
| FY 2023 | $2.4M | $0 | — | — | -$37.9M | -$53.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UPB // BETA —
ANTX // BETA —